Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis

Gene Therapy

Volumn 12, Issue 14, 2005, Pages 1145-1153

  Louie, K A ^a   Weiner, L P ^a   Du, J ^a   Kochounian, H H ^a   Fling, S P ^b   Wei, W ^a   McMillan, M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Allogeneic fibroblasts; Implants; Multiple sclerosis; Retroviral vector; SJL mice

Indexed keywords

EPITOPE; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL BASED GENE THERAPY; CELL SECRETION; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE CONSTRUCT; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSDUCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE; DIFFUSION CHAMBERS, CULTURE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FIBROBLASTS; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PROTEOLIPIDS; RETROVIRIDAE; TRANSDUCTION, GENETIC;

ANIMALIA; MURINAE;

EID: 22744449565     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302503     Document Type: Article

References (70)

1. Anderson WF. Human gene therapy. Science 1992; 256: 808-813.
2. Balicki D, Beutler E. Gene therapy of human disease. Medicine (Baltimore) 2002; 81: 69-86.
3. Anderson WF. The current status of clinical gene therapy. Hum Gene Ther 2002; 13: 1261-1262.
4. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
5. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci 2002; 3: 291-301.
6. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-187.
7. Raine CS. Multiple sclerosis: a pivotal role for the T cell in lesion development. Neuropathol Appl Neurobiol 1991; 17: 265-274.
8. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999; 283: 1277-1278.
9. Barcellos LF et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002; 125: 150-158.
10. Barcellos LF et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003; 72: 710-716.
11. Coraddu F et al. HLA typing in the United Kingdom multiple sclerosis genome screen. Neurogenetics 1998; 2: 24-33.
12. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972; 1: 1240-1241.
13. Prat E, Martin R. The immunopathogenesis of multiple sclerosis. J Rehabil Res Dev 2002; 39: 187-199.
14. Baker D, Hankey DJ. Gene therapy in autoimmune, demyelinating disease of the central nervous system. Gene Therapy 2003; 10: 844-853.
15. Furlan R, Pluchino S, Martino G. The therapeutic use of gene therapy in inflammatory demyelinating diseases of the central nervous system. Curr Opin Neurol 2003; 16: 385-392.
16. Mathisen PM, Tuohy VK. Gene therapy in experimental autoimmune encephalomyelitis. J Clin Immunol 2000; 20: 327-333.
17. Seroogy CM, Fathman CG. The application of gene therapy in autoimmune diseases. Gene Therapy 2000; 7: 9-13.
18. Tarner IH et al. Treatment of autoimmune disease by adoptive cellular gene therapy. Ann NY Acad Sci 2003; 998: 512-519.
19. Brown AM, McFarlin DE. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest 1981; 45: 278-284.
20. Kuchroo VK et al. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol 2002; 20: 101-123.
21. Zhang J et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179: 973-984.
22. Sobel RA, Greer JM, Kuchroo VK. Minireview: autoimmune responses to myelin proteolipid protein. Neurochem Res 1994; 19: 915-921.
23. Tuohy VK et al. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J Immunol 1989; 142: 1523-1527.
24. Tuohy VK et al. Myelin proteolipid protein: minimum sequence requirements for active induction of autoimmune encephalomyelitis in SWR/J and SJL/J mice. J Neuroimmunol 1992; 39: 67-74.
25. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182: 75-85.
26. Vanderlugt CL et al. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol 2000; 164: 670-678.
27. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 1992; 358: 155-157.
28. Tuohy VK et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998; 164: 93-100.
29. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2: 85-95.
30. Weiner LP et al. Gene therapy in a murine model for clinical application to multiple sclerosis. Ann Neurol 2004; 55: 390-399.
31. Sakai K et al. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol 1988; 19: 21-32.
32. Martin R et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990; 145: 540-548.
33. Ota K et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346: 183-187.
34. Pelfrey CM et al. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J Immunol 2000; 165: 1641-1651.
35. Tejada-Simon MV, Hong J, Rivera VM, Zhang JZ. Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol 2001; 31: 907-917.
36. Gierasch LM. Signal sequences. Biochem 1989; 28: 923-930.
37. Huang S, Paulauskis JD, Kobzik L. Rat KC cDNA cloning and mRNA expression in lung macrophages and fibroblasts. Biochem Biophys Res Commun 1992; 184: 922-929.
38. Tibell A et al. Survival of macroencapsulated allogeneic parathyroid tissue one year after transplantation in nonimmunosuppressed humans. Cell Transplant 2001; 10: 591-599.
39. Yanay O et al. Long-term erythropoietin gene expression from transduced cells in bioisolator devices. Hum Gene Ther 2003; 14: 1587-1593.
40. Goodin DS et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
41. Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001; 49: 281-284.
42. Martin R, Sturzebecher CS, McFarland HF. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat Immunol 2001; 2: 785-788.
43. Steinman L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr Opin Immunol 2001; 13: 597-600.
44. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003; 3: 223-232.
45. Chen LZ et al. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1. Proc Natl Acad Sci USA 1998; 95: 12516-12521.
46. Costa GL et al. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J Immunol 2001; 167: 2379-2387.
47. Mathisen PM et al. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J Exp Med 1997; 186: 159-164.
48. Shaw MK et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J Exp Med 1997; 185: 1711-1714.
49. Yin L et al. Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease. J Immunol 2001; 167: 6105-6112.
50. Garren H et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 2001; 15: 15-22.
51. Chen CC, Rivera A, Dougherty JP, Ron Y. Complete protection from relapsing experimental autoimmune encephalomyelitis induced by syngeneic B cells expressing the autoantigen. Blood 2004; 103: 4616-4618.
52. Melo ME et al. Gene transfer of Ig-fusion proteins into B cells prevents and treats autoimmune diseases. J Immunol 2002; 168: 4788-4795.
53. Pedotti R et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001; 2: 216-222.
54. Anderson AC et al. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J Exp Med 2000; 191: 761-770.
55. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24: 511-514.
56. Tian J et al. Antigen-based immunotherapy for autoimmune disease: from animal models to humans? Immunol Today 1999; 20: 190-195.
57. Bielekova B et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167-1175.
58. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001; 79: 552-565.
59. Genain CP, Zamvil SS. Specific immunotherapy: one size does not fit all. Nat Med 2000; 6: 1098-1100.
60. Kappos L et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000; 6: 1176-1182.
61. Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172: 2731-2738.
62. Chou YK et al. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. J Neuroimmunol 1992; 38: 105-113.
63. Correale J et al. Isolation and characterization of autoreactive proteolipid protein-peptide specific T-cell clones from multiple sclerosis patients. Neurology 1995; 45: 1370-1378.
64. Trotter JL et al. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects. J Neuroimmunol 1998; 84: 172-178.
65. Freshney RI. Culture of Animal Cells, 2nd edn. Alan R. Liss, Inc.: New York, 1987.
66. Oi VT, Jones PP, Goding JW, Herzenberg LA. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr Top Microbiol Immunol 1978; 81: 115-120.
67. Ozato K, Hansen TH, Sachs DH. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol 1980; 125: 2473-2477.
68. Kozak M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 1984; 12: 857-872.
69. Fling SP et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis. Proc Natl Acad Sci USA 2001; 98: 1160-1165.
70. Pear WS, Scott ML, Nolan GP In: Robbins P (ed). Methods in Molecular Medicine: Gene Therapy Protocols. Humana Press: Totowa, NJ, 1996, pp 41-57.